What did @jbpeptidegirlie actually say?
The creator, who goes by Isja, laid out cycling protocols for several peptides: tirzepatide (3 to 6 months continuous with short pauses), a "glow blend" containing GHK-Cu, BPC-157, and TB-500 (6 to 8 weeks on, 4 weeks off), NAD+ (4 to 8 weeks on, 1 to 2 weeks off), and growth hormone peptides like CJC-1295 and ipamorelin (8 to 12 weeks on, 4 weeks off). Her core argument is that cycling prevents "receptor fatigue" and allows the pituitary gland to reset. She framed tirzepatide as an exception, saying it works by "regulating your GLP-1 and GIP hormones" and therefore doesn't require official cycling breaks.
She also offered a gym rest day analogy, which is a reasonable lay explanation for the concept even if the underlying physiology is more complicated. The video has 45,000-plus views, which means these specific timelines are reaching a real audience making real decisions about self-administered compounds.
Does the science back this up?
Partially, and the parts that are wrong matter. The tirzepatide framing is the most defensible. Clinical trial data, including the SURMOUNT-1 trial (Jastreboff et al., 2022, New England Journal of Medicine), supports extended continuous use. The GLP-1 and GIP dual-agonist mechanism doesn't show the rapid receptor downregulation seen in some other peptide classes, and no major clinical guideline recommends routine drug holidays for tirzepatide.
The cycling logic for BPC-157 and TB-500 is harder to evaluate because there are no robust human clinical trials establishing cycling intervals for either compound. Most available data comes from rodent studies. Zlatić et al. (2022, Biomedicines) reviewed BPC-157's proposed mechanisms but noted the evidence base remains largely preclinical. TB-500 (thymosin beta-4) similarly lacks human pharmacokinetic data that would justify a specific 6-to-8-week window. Recommending precise timelines without that data is speculative, even if the general idea of periodic breaks is reasonable.
The CJC-1295 and ipamorelin cycling advice has more biological plausibility. Prolonged GHRH analogue stimulation can desensitize pituitary somatotrophs. Hartman et al. (1993, Journal of Clinical Endocrinology and Metabolism) documented pituitary desensitization with continuous GHRH administration, supporting the case for intermittent use. But the specific 8-to-12-week and 4-week rest numbers are not drawn from published protocols.
What did they get wrong (or right)?
The biggest problem is false precision. Isja presents specific cycle lengths like "6 to 8 weeks" for BPC-157 and "4 to 8 weeks" for NAD+ with a confidence the science does not support. These numbers appear to originate from bodybuilding forum conventions, not peer-reviewed pharmacology. Presenting them as established fact to 45,000 viewers is misleading.
She also conflates NAD+ with peptides. NAD+ is a coenzyme, not a peptide. Grouping it into a peptide cycling framework without that distinction muddies the educational value she's aiming for.
On the other hand, she gets the conceptual case for cycling right. The pituitary reset rationale for growth hormone secretagogues is biologically grounded. Her point that tirzepatide doesn't follow the same cycling rules as research peptides is accurate and reflects current prescribing patterns. She disclosed upfront that this is not medical advice. That disclaimer matters, even if it doesn't neutralize the specific claims.
What should you actually know?
If you're using any of the peptides named in this video, the most important thing to understand is that almost none of them have established human dosing or cycling protocols validated in clinical trials. Tirzepatide is the exception. It is FDA-approved, and its long-term use data comes from large randomized controlled trials with thousands of participants.
BPC-157 and TB-500 are not approved by the FDA for human use and are classified as research compounds. Any cycling schedule you follow for them is, at best, an educated extrapolation from animal data and anecdotal reports. The same applies to CJC-1295 and ipamorelin, which are not FDA-approved peptides despite being widely discussed in optimization communities.
Receptor desensitization is a real pharmacological phenomenon worth understanding, but the specific timelines Isja cites should not be treated as clinical guidance. Consult a licensed provider who can review your individual health status before starting, adjusting, or cycling any of these compounds.